Condition: Migraine Disorder · Episodic Migraine · Sponsor: IRCCS National Neurological Institute "C. Mondino" Foundation
The investigators aim to assess and compare neurophysiological and biochemical changes induced by a 3-month treatment with atogepant (60 mg daily) in patients with high-frequency episodic migraine (8-14 monthly migraine days). Evaluations will include neurophysiological assessments (High-Density EEG, nociceptive reflexes, and visual evoked potentials) and biomolecular profiling (gene expression of endocannabinoid catabolizing enzymes, CGRP and PACAP plasma levels, and headache-specific microRNAs). Outputs will contribute to defining predictors of atogepant response, elucidating its effects on brain connectivity, excitability, and CGRP/endocannabinoid pathways, and identifying alternative therapeutic targets for non-responders.
This description comes directly from the study's public registry record.
Francescantonio Cammarota, MD · 00390382380425 · francesco.cammarota@mondino.it
Cinzia Fattore · 00390382380385 · cinzia.fattore@mondino.it
Always discuss trial participation with your own doctor first.
| Headache Science & Neurorehabilitation Center | Pavia, PAVIA, Italy | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06882122